Chart-Typ:
Zeitraum:
| XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated... ► Artikel lesen |
| Halozyme Therapeutics, Inc.: Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon Technology | Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors | Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations | FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted... ► Artikel lesen |
| Palvella Therapeutics Inc.: FDA Grants Rolling Review of Palvella's QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations | FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted Palvella remains on... ► Artikel lesen |
| Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PARDES BIOSCIENCES INC finden Sie auf Wallstreet Online.